Characterization of biased airway smooth muscle TAS2R agonists for treating asthma
偏向气道平滑肌 TAS2R 激动剂治疗哮喘的表征
基本信息
- 批准号:10322110
- 负责人:
- 金额:$ 54.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAgeAgonistAir MovementsArrestinsAsthmaBackBindingBinding SitesBiochemicalBiologyBronchial SpasmBronchodilator AgentsCell modelCellsCharacteristicsClinicalCollectionComplexCouplingCytometryDataDiseaseDockingDoseEngineeringEthnic OriginFunctional disorderG-Protein-Coupled ReceptorsGTP-Binding ProteinsGenetic EngineeringHumanInterventionLearningLibrariesLigand BindingLigandsLungMagnetismMethodsModalityModelingMolecular ConformationMorbidity - disease rateObstructionOutcomePathway interactionsPatientsPharmaceutical PreparationsPharmacologyPhenotypePhysiologicalPhysiologyPreventionProcessPropertyPublic HealthRelaxationResistanceSignal TransductionSliceSmooth Muscle MyocytesStructureSystemTachyphylaxisTaste BudsTechniquesTherapeuticTimeTranslationsWorkairway obstructionasthmaticattenuationbasebeta-arrestincell typedesensitizationdisorder controlexperienceexperimental studyin silicointerestmodels and simulationmolecular modelingmortalitynovelpharmacophorepredictive modelingpreventreceptorrecruitrespiratory smooth muscleresponsesimulationthree dimensional structuretreatment optimizationvirtualvirtual screening
项目摘要
Asthma remains a major public health issue worldwide, affecting all ages and ethnicities, with 50% of patients
experiencing inadequate control of the disease. Constricted airways from contraction of airway smooth muscle
is the major cause of airflow obstruction, and morbidity and mortality, in asthma. Despite this key point for
intervention, only one class of direct bronchodilators (-agonists) are available for treatment, and they are
suboptimal for many patients. We have discovered bitter taste receptors (TAS2Rs) on human airway smooth
muscle (HASM) cells which signal by a unique mechanism. When activated, TAS2Rs markedly relax HASM and
relieve airway obstruction that is otherwise resistant to -agonists. However, the known TAS2R agonists have
low affinity and evoke desensitization (tachyphylaxis) of the relaxation response over time via -arrestin
mechanisms. The overarching hypothesis is that TAS2R agonists with novel structures can be highly effective
in relaxing airways in an asthmatic milieu and yet not evoke tachyphylaxis. The broad long-term objectives are
to determine the 3D structures and binding sites of two TAS2Rs expressed on HASM (R5 and R14) and then
use these structures to perform virtual docking of an agnostic ultra-large compound library to identify potential
ligands. These hits will be examined in engineered model cells, but will be most intensely studied within the
context of the physiology of HASM cells, and human airways, under asthmatic conditions to delineate novel ways
to engage the receptor that are biased towards relaxation and away from desensitization. Aim 1 will
computationally determine the structures and binding sites for R5 and R14 using methods that include 13 trillion
combinations of the residues to determine favorable energy conformations of inactive and active states. The
structures will be used to dock compounds from a highly diverse library. These will be studied in Aim 2 to
determine potency and efficacy in genetically engineered model cells and in HASM cells from nonasthmatic and
asthmatic lungs. In Aim 3, the most favorable compounds will be studied to ascertain -arrestin engagement
and biasing away from desensitization in model cells, HASM cells, and human lungs under asthmatic conditions.
Results from Aims2/3 will be fed back into Aim1 to further refine a model of biased agonists for these HASM
TAS2Rs. Based on our preliminary data that support all three Aims, we will learn about the structural
requirements for biasing for these receptors. And, we anticipate that multiple highly effective agonists with
unexpected structures will be identified and that their bronchodilating properties in asthma will represent a new
class of powerful non-desensitizing agents for treating and preventing bronchospasm.
哮喘仍然是全球主要的公共卫生问题,影响所有年龄段和种族,50% 的患者患有哮喘
疾病控制不力。气道平滑肌收缩导致气道收缩
是哮喘气流阻塞、发病率和死亡率的主要原因。尽管有这个关键点
在干预期间,只有一类直接支气管扩张剂(激动剂)可用于治疗,并且它们
对于许多患者来说不是最理想的。我们在人类呼吸道平滑肌上发现了苦味受体(TAS2R)
肌肉(HASM)细胞通过独特的机制发出信号。激活后,TAS2R 会显着放松 HASM,
缓解对 激动剂耐药的气道阻塞。然而,已知的 TAS2R 激动剂
随着时间的推移,通过 -arrestin 产生低亲和力并引起松弛反应脱敏(快速耐受)
机制。总体假设是具有新颖结构的 TAS2R 激动剂可以非常有效
在哮喘环境中放松气道,但不会引起快速耐受。广泛的长期目标是
确定 HASM 上表达的两个 TAS2R(R5 和 R14)的 3D 结构和结合位点,然后
使用这些结构对不可知的超大型化合物库进行虚拟对接,以识别潜在的
配体。这些命中将在工程模型细胞中进行检查,但将在
哮喘条件下 HASM 细胞和人类呼吸道的生理学背景,以描绘新的方法
接合偏向松弛且远离脱敏的受体。目标1将
使用包含 13 万亿的方法计算确定 R5 和 R14 的结构和结合位点
残基的组合以确定非活性和活性状态的有利能量构象。这
结构将用于对接高度多样化的库中的化合物。这些将在目标 2 中进行研究
确定基因工程模型细胞和来自非哮喘和哮喘患者的 HASM 细胞的效力和功效
哮喘肺。在目标 3 中,将研究最有利的化合物以确定 -arrestin 的参与
在哮喘条件下模型细胞、HASM 细胞和人肺中偏向脱敏。
Aims2/3 的结果将反馈至 Aim1,以进一步完善这些 HASM 的偏向激动剂模型
TAS2R。根据支持所有三个目标的初步数据,我们将了解结构
这些受体的偏置要求。而且,我们预计多种高效激动剂
将鉴定出意想不到的结构,并且它们在哮喘中的支气管扩张特性将代表一种新的
一类用于治疗和预防支气管痉挛的强效非脱敏剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen B Liggett其他文献
Stephen B Liggett的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen B Liggett', 18)}}的其他基金
Characterization of biased airway smooth muscle TAS2R agonists for treating asthma
偏向气道平滑肌 TAS2R 激动剂治疗哮喘的表征
- 批准号:
10543121 - 财政年份:2021
- 资助金额:
$ 54.16万 - 项目类别:
Molecular properties of B-adrenergic receptors in Asthma
哮喘中 B-肾上腺素能受体的分子特性
- 批准号:
9130410 - 财政年份:2015
- 资助金额:
$ 54.16万 - 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶标
- 批准号:
10465061 - 财政年份:2013
- 资助金额:
$ 54.16万 - 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶点
- 批准号:
10683126 - 财政年份:2013
- 资助金额:
$ 54.16万 - 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶标
- 批准号:
10238021 - 财政年份:2013
- 资助金额:
$ 54.16万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
7783557 - 财政年份:2010
- 资助金额:
$ 54.16万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8403707 - 财政年份:2010
- 资助金额:
$ 54.16万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8197661 - 财政年份:2010
- 资助金额:
$ 54.16万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8010837 - 财政年份:2010
- 资助金额:
$ 54.16万 - 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
- 批准号:
8544624 - 财政年份:2010
- 资助金额:
$ 54.16万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 54.16万 - 项目类别:
Continuing Grant